
    
      The drug being tested in this survey is called Leuprorelin for Injection Kit 22.5 mg.
      Leuprorelin is being tested to treat people who have premenopausal breast cancer.

      This survey will look at the safety in patients with premenopausal breast cancer receiving
      the drug in the routine clinical setting.

      The survey will enroll approximately 300 patients.

      - Leuprorelin

      This multi-center survey will be conducted in Japan.
    
  